NAD+ Injections in Clinical Practice

Guideline-Based Recommendations

The American Society for Parenteral and Enteral Nutrition recommends the oral/enteral route for niacin supplementation whenever the gastrointestinal tract is functional, as it has established safety data and effectively increases blood NAD+ levels 1
For patients requiring parenteral nutrition due to non-functional GI tract, guidelines recommend standard niacin at 40 mg/day, not injectable NAD+, to maintain adequate NAD+ levels 1, 2
The American College of Nutrition recommends daily intake of niacin (NAD+ precursor): 16 mg/day for adult males and 14 mg/day for adult females 1
Parenteral nutrition dosing of niacin is 40 mg/day when the oral route is unavailable 1, 2
The upper safety limit for nicotinamide is approximately 900 mg/day for adults (12.5 mg/kg body weight/day) 1, 3

No published randomized controlled trials exist for NAD+ infusions in humans in medical databases 2
FDA labeling for intravenous NAD+ lists only cosmetic applications, not therapeutic medical indications 2
The American Academy of Physical Medicine and Rehabilitation does not recommend NAD+ patches due to lack of clinical evidence 2
NAD+ is a large, charged molecule with poor bioavailability and stability when injected intramuscularly or intravenously 3
High doses of nicotinic acid can cause flushing, nausea, vomiting, liver toxicity, blurred vision, and impaired glucose tolerance 2
The upper intake limit for free nicotinic acid is only 10 mg/day due to flushing effects seen at 30 mg/day 1, 2

Advise consumption of niacin-rich foods: fortified packaged foods, meat and poultry, red fish (tuna, salmon), nuts, legumes, and seeds 1, 2
Measure blood or tissue NAD+ levels if pellagra symptoms are present (diarrhea, dermatitis, dementia) 2
Risk factors for niacin deficiency include: corn-based diet, malnutrition, chronic alcoholism, and malabsorption states 2
Use oral nicotinic acid (15-20 mg/day) or nicotinamide (300 mg/day) for pellagra treatment 2
Do not use NAD+ infusions for therapeutic purposes outside of research protocols due to lack of guideline support, poor pharmacokinetics, and absent proven clinical benefit 2

The most common side effects of NMN supplementation are gastrointestinal symptoms (nausea, vomiting, diarrhea) 1
Age-related decline in cellular NAD+ levels has been documented in both men (P = 0.001) and women (P = 0.01), with changes consistent with increased PARP activation and decreased SIRT1 activity 4, 5
While NAD+ levels decline with age, supplementation guidelines remain focused on oral precursors, not injections 1

Do not assume injectable NAD+ is superior to oral precursors—no evidence supports this claim 2, 3
Do not confuse niacin precursors with direct NAD+ administration—they have different safety profiles and evidence bases 1
Do not use nicotinic acid forms without warning patients about flushing at doses as low as 30 mg 1, 2
Do not recommend NAD+ injections based on marketing claims—they lack regulatory approval for therapeutic use 2